Lantern Pharma Inc. (NASDAQ:LTRN) Short Interest Down 19.8% in September

Lantern Pharma Inc. (NASDAQ:LTRN) was the recipient of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 179,100 shares, a decrease of 19.8% from the August 31st total of 223,300 shares. Approximately 2.2% of the company’s stock are sold short. Based on an average daily trading volume, of 54,400 shares, the days-to-cover ratio is presently 3.3 days.

Lantern Pharma Price Performance

Lantern Pharma stock traded down $0.06 during trading hours on Friday, hitting $3.78. The company had a trading volume of 52,786 shares, compared to its average volume of 149,754. The firm has a market capitalization of $40.62 million, a P/E ratio of -2.32 and a beta of 1.56. The firm’s fifty day moving average is $4.05 and its 200-day moving average is $5.41. Lantern Pharma has a fifty-two week low of $2.38 and a fifty-two week high of $11.99.

Lantern Pharma (NASDAQ:LTRN) last posted its earnings results on Thursday, August 8th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.09. During the same quarter in the prior year, the company earned ($0.44) earnings per share. Analysts anticipate that Lantern Pharma will post -2.12 earnings per share for the current year.

Institutional Trading of Lantern Pharma

Several large investors have recently modified their holdings of LTRN. Tocqueville Asset Management L.P. bought a new stake in Lantern Pharma in the 1st quarter valued at $167,000. Westside Investment Management Inc. bought a new stake in Lantern Pharma in the 2nd quarter valued at $54,000. CM Management LLC boosted its holdings in Lantern Pharma by 23.1% in the 2nd quarter. CM Management LLC now owns 80,000 shares of the company’s stock valued at $374,000 after purchasing an additional 15,000 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Lantern Pharma by 55.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 18,413 shares of the company’s stock valued at $86,000 after purchasing an additional 6,585 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Lantern Pharma by 24.5% in the 2nd quarter. Renaissance Technologies LLC now owns 81,800 shares of the company’s stock valued at $382,000 after purchasing an additional 16,100 shares during the period. 28.62% of the stock is owned by institutional investors.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.